Table III.
Insulin levels.
| 21th day | At the end of the study | |||
|---|---|---|---|---|
| Study groups | Median (IQR) | Differences from shama | Median (IQR) | Differences from 21th dayb |
| Groups | ||||
| Sham (n=9) | 117.32 (11.29) | 119.92 (14.15) | Z=2.310; P=0.021 | |
| PCOS control (n=9) | 198.78 (15.17) | Z=4.573; P<0.001 | 194.52 (18.91) | Z=0.059; P=0.953 |
| Merformin (n=8) | 184.57 (28.14) | Z=2.918; P=0.012 | 106.63 (53.97) | Z=2.521; P=0.012 |
| Metformin + PDE 4 inhibitor (n=10) | 177.83 (28.69) | Z=3.085; P=0.006 | 97.12 (17.52) | Z=2.803; P=0.005 |
| Comparisons of the groupsc | χ2=21.864; P<0.001 | χ2=25.347; P<0.001 | ||
a
Bonferroni corrected Mann-Whitney test results.
b
Wilcoxon signed rank test results.
c
Kruskal-Wallis non-parametric analyzing of variance test results. PCOS, polycystic ovary syndrome; PDE4i, phosphodiesterase 4 inhibitor; IQR, interquartile range.